New hope for endometriosis pain: relugolix combo under Real-World study
NCT ID NCT07440043
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will follow 33 women with endometriosis who are taking relugolix combination therapy for pelvic pain. Researchers will track pain changes over 24 weeks using a standard pain scale, along with other symptoms and safety. The goal is to see how well this treatment works in routine clinical practice, outside of strict trial conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Relugolix combination therapy (oral GnRH receptor antagonist)
What this could lead to
If successful, this could confirm that relugolix combination therapy works well for endometriosis pain in everyday medical practice, not just in controlled trials.
What could go wrong
This is a small, single-center observational study with only 33 participants, so results may not apply to everyone. It is not yet recruiting, and real-world effectiveness can differ from clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••